PepGen Shares Fall on Mixed Trial Results for Muscle Disorder Drug

Dow Jones03-31

By Katherine Hamilton

PepGen shares fell after the company shared mixed results for its muscle-disorder treatment.

The stock slid 48% to $2.20 in after-hours trading Monday. Shares are down 35% this year.

PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splicing in muscle tissue among patients.

Patients taking 5 mg/kg of PGN-EDODM1 showed a mean splicing correction of 7.3%, just above the 6.8% in placebo-treated patients, PepGen said.

The mean splicing correction rate among treated patients was weighed down by one patient, who had a worsening in splicing correction while taking the drug. The patient showed 70.8% worsening in splicing correction, dragging the group's average splicing correction down from 22.9%.

No meaningful improvements were observed in a 10-meter walk/run test or in handgrip strength.

PepGen does believe the total safety and efficacy results support the potential of the ongoing trial of patients taking 10 mg/kg. Clinical results for that trial are expected in the second half of 2026.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 30, 2026 18:09 ET (22:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623322872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 06:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623322872","market":"us","top_or_hot":-1,"title":"PepGen Shares Fall on Mixed Trial Results for Muscle Disorder Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  PepGen shares fell after the company shared mixed results for its muscle-disorder treatment. \n</p>\n<p>\n  The stock slid 48% to $2.20 in after-hours trading Monday. Shares are down 35% this year. \n</p>\n<p>\n  PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splicing in muscle tissue among patients. \n</p>\n<p>\n  Patients taking 5 mg/kg of PGN-EDODM1 showed a mean splicing correction of 7.3%, just above the 6.8% in placebo-treated patients, PepGen said. \n</p>\n<p>\n  The mean splicing correction rate among treated patients was weighed down by one patient, who had a worsening in splicing correction while taking the drug. The patient showed 70.8% worsening in splicing correction, dragging the group's average splicing correction down from 22.9%. \n</p>\n<p>\n  No meaningful improvements were observed in a 10-meter walk/run test or in handgrip strength. \n</p>\n<p>\n  PepGen does believe the total safety and efficacy results support the potential of the ongoing trial of patients taking 10 mg/kg. Clinical results for that trial are expected in the second half of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 18:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PepGen Shares Fall on Mixed Trial Results for Muscle Disorder Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPepGen Shares Fall on Mixed Trial Results for Muscle Disorder Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-31 06:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  PepGen shares fell after the company shared mixed results for its muscle-disorder treatment. \n</p>\n<p>\n  The stock slid 48% to $2.20 in after-hours trading Monday. Shares are down 35% this year. \n</p>\n<p>\n  PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splicing in muscle tissue among patients. \n</p>\n<p>\n  Patients taking 5 mg/kg of PGN-EDODM1 showed a mean splicing correction of 7.3%, just above the 6.8% in placebo-treated patients, PepGen said. \n</p>\n<p>\n  The mean splicing correction rate among treated patients was weighed down by one patient, who had a worsening in splicing correction while taking the drug. The patient showed 70.8% worsening in splicing correction, dragging the group's average splicing correction down from 22.9%. \n</p>\n<p>\n  No meaningful improvements were observed in a 10-meter walk/run test or in handgrip strength. \n</p>\n<p>\n  PepGen does believe the total safety and efficacy results support the potential of the ongoing trial of patients taking 10 mg/kg. Clinical results for that trial are expected in the second half of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 18:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEPG","symbol_name":"PepGen Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2623322872","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623322872","pubTimestamp":1774908540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"PepGen shares fell after the company shared mixed results for its muscle-disorder treatment.The stock slid 48% to $2.20 in after-hours trading Monday. Shares are down 35% this year.PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splicing in muscle tissue among patients.Patients taking 5 mg/kg of PGN-EDODM1 showed a mean splicing correction of 7.3%, just above the 6.8% in placebo-treated patients, PepGen said.The mean splicing correction rate among treated patients was weighed down by one patient, who had a worsening in splicing correction while taking the drug. The patient showed 70.8% worsening in splicing correction, dragging the group's average splicing correction down from 22.9%.No meaningful improvements were observed in a 10-meter walk/run test or in handgrip strength.PepGen does believe the total safety and efficacy results support the potential of the ong","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEPG":"PepGen Inc.","BK4139":"生物科技"},"translate_title":"PepGen股价因肌肉疾病药物试验结果好坏参半而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEPG":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  PepGen shares fell after the company shared mixed results for its muscle-disorder treatment. \n\n\n  The stock slid 48% to $2.20 in after-hours trading Monday. Shares are down 35% this year. \n\n\n  PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splicing in muscle tissue among patients. \n\n\n  Patients taking 5 mg/kg of PGN-EDODM1 showed a mean splicing correction of 7.3%, just above the 6.8% in placebo-treated patients, PepGen said. \n\n\n  The mean splicing correction rate among treated patients was weighed down by one patient, who had a worsening in splicing correction while taking the drug. The patient showed 70.8% worsening in splicing correction, dragging the group's average splicing correction down from 22.9%. \n\n\n  No meaningful improvements were observed in a 10-meter walk/run test or in handgrip strength. \n\n\n  PepGen does believe the total safety and efficacy results support the potential of the ongoing trial of patients taking 10 mg/kg. Clinical results for that trial are expected in the second half of 2026. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 18:09 ET (22:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623322872","isCrawlerRequest":true}